|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table S2. Calculated variance inflation factors   |  |  | | --- | --- | |  | VIF |  |  |  | | --- | --- | | Category II / Category I | 2.347 | | Category III / Category I | 2.364 | | Category III / Category II | 1.788 | | BMI | 1.065 | | Fasting plasma glucose | 1.079 | | Use of GLP‐1 receptor agonist | 2.433 | | Use of DPP-4 inhibitor | 2.342 | | Use of SGLT2 inhibitor | 1.353 | | Number of concomitant antidiabetic drugs | 1.809 |   VIF: variance inflation factor, BMI: body mass index, GLP-1: glucagon-like peptide 1, DPP-4: dipeptidyl peptidase 4, SGLT2: sodium-glucose cotransporter 2. |